--- a
+++ b/clusters/9knumclustersv2/clust_1216.txt
@@ -0,0 +1,26 @@
+INCLUSION CRITERIA FOR SECOND-LINE THERAPY: For patients with known hepatic metastases, AST and ALT =<  X the upper normal limit of institution's normal range
+INCLUSION CRITERIA FOR THIRD-LINE THERAPY: AST and ALT =<  X the upper normal limit of institution's normal range
+INCLUSION CRITERIA FOR THIRD-LINE THERAPY: For patients with known hepatic metastases, AST and ALT =<  X the upper normal limit of institution's normal range
+Patients with -hydroxyindoleacetic acid (HIAA) levels above or below the upper limit of normal range (normal:  to  mg/ hours) and those with unknown values at baseline are allowed to participate
+AST and ALT ? . X the upper normal limit of institution's normal range
+Total bilirubin ? . X the upper normal limit of institution's normal range
+PT and PTT must be ? . X upper normal limit of institution's normal range
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x the upper normal limit of institution's normal range, at the time of enrollment; for subjects with liver metastases, AST and ALT =<  x the upper normal limit of institution's normal range are acceptable as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia
+Total bilirubin =< . x the upper normal limit of institution's normal range, at the time of enrollment; for subjects with liver metastases, total bilirubin > . - . x the upper normal limit of institution's normal range are acceptable as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia
+Must have had an elevated serum CA level twice the upper limit of normal (per reference lab normal range) measured within  weeks of enrollment.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x the upper normal limit of institution's normal range; for subjects with liver metastases, AST and ALT <  x the upper normal limit of institution's normal range are acceptable as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia
+Total bilirubin =< . x the upper normal limit of institution's normal range; for subjects with liver metastases, total bilirubin > . - . x the upper normal limit of institution's normal range are acceptable as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia
+Bilirubin =< . X the upper normal limit of institution's normal range
+Partial thromboplastin time (PTT) must be =<  X upper normal limit of institution's normal range; subjects on anticoagulant (such as coumadin) must have a PTT =<  X upper normal limit of institution's normal range
+Non-fasting bilirubin =< . X the upper normal limit of institution's normal range
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< .  the upper normal limit of institution's normal range; for subjects with liver metastases, AST and ALT <   the upper normal limit of institution's normal range AS LONG AS THERE IS NO persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia
+Non-fasting direct bilirubin =< .  the upper normal limit of institution's normal range
+Partial thromboplastin time (PTT) must be =< .  upper normal limit of institution's normal range
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< .  the upper normal limit of institution's normal range; for subjects with liver metastases, AST and ALT <   the upper normal limit of institution's normal range are acceptable AS LONG AS THERE IS NO persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia; the combination of -FU and oxaliplatin is known to be safe to be administered in patients with such abnormal liver function tests
+Non-fasting direct bilirubin =< .  the upper normal limit of institution's normal range; for subjects with liver metastases, non-fasting direct bilirubin > .-. x the upper normal limit of institution's normal range are acceptable AS LONG AS THERE IS NO persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia; the combination of -FU and oxaliplatin is known to be safe to be administered in patients with such abnormal liver function tests
+Partial thromboplastin time (PTT) must be =< .  upper normal limit of institution's normal range
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . X the upper normal limit of institution's normal range; for subjects with liver metastases, AST and ALT <  X the upper normal limit of institution's normal range AS LONG AS THERE IS NO persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia
+Non-fasting bilirubin =< . X the upper normal limit of institution's normal range; non-fasting bilirubin . - . X the upper normal limit of institution's normal range are acceptable AS LONG AS THERE IS NO persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia
+Hepatic function: AST and ALT ? .  the upper normal limit of institution's normal range. For subjects with liver metastases, AST and ALT ?   the upper normal limit of institution's normal range;
+Bilirubin: ? .  the upper normal limit of institution's normal range.
+Subjects have adequate bone marrow, renal, and hepatic function as follows: Bone marrow: Absolute neutrophil count (ANC) >/= ,/mm Platelets >/= ,/mm; Hemoglobin >/= . g/dL Renal function: Serum creatinine </= . times the upper limit of the institution's normal range Hepatic function: Bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) </= . times the upper limit of the institution's normal range. Subjects with liver metastasis may have an AST and ALT of </= . x the upper limit of normal.